SYNTEKABIO
Syntekabio is a Korean biotech firm, developing personal genome map which is expected to enable personalized medical service. The company also provides a technology for collecting and integrating decrypted whole genome data.
SYNTEKABIO
Industry:
Biotechnology Health Care Information Technology Medical
Founded:
2009-09-15
Address:
Daejeon, Taejon-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.syntekabio.com
Total Employee:
11+
Status:
Active
Contact:
212-371-2544
Email Addresses:
[email protected]
Total Funding:
211.54 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Google Tag Manager Google Analytics LetsEncrypt Amazon SSL By Default Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Molecular Health
Molecular Health offers software solutions for evidence-based healthcare decision support and smarter drug development.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Tridiuum
Tridiuum is a digital health company that is advancing the treatment of behavioral health conditions.
Current Employees Featured
Founder
Stock Details
Investors List
Korea Investment Partners
Korea Investment Partners investment in Post-IPO Equity - Syntekabio
Timewise Investment
Timewise Investment investment in Series C - Syntekabio
Altos Ventures
Altos Ventures investment in Series C - Syntekabio
Yuhan Corporation
Yuhan Corporation investment in Series C - Syntekabio
KB Securities
KB Securities investment in Series C - Syntekabio
Saehan Venture Capital
Saehan Venture Capital investment in Series C - Syntekabio
Smilegate Investment
Smilegate Investment investment in Series B - Syntekabio
Altos Ventures
Altos Ventures investment in Series B - Syntekabio
Yozma Group Korea
Yozma Group Korea investment in Series B - Syntekabio
Korea Development Bank
Korea Development Bank investment in Series B - Syntekabio
Official Site Inspections
http://www.syntekabio.com Semrush global rank: 4.16 M Semrush visits lastest month: 2.46 K
- Host name: 128.154.54.34.bc.googleusercontent.com
- IP address: 34.54.154.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Syntekabio"
Syntekabio
Syntekabio has identified over 100 targets to accelerate the discovery of new drug candidates and provide medications to more patients. Show More. AI-automation DeepMatcher® Small …See details»
Syntekabio - Crunchbase Company Profile & Funding
Organization. Syntekabio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Syntekabio is a public company, listed on the …See details»
Syntekabio - Lab Manager
Feb 8, 2021 Syntekabio Syntekabio is an AI and NGS-based drug development company, utilizing a genomic database and AI to predict and identify new molecular entities to develop …See details»
Syntekabio
Syntekabio uses DMC to discover new drug candidates for various targets of domestic and global pharmaceutical companies, biotech and research institutes. We use an R-group DB for drug …See details»
Syntekabio Company Profile | Management and Employees List
Syntekabio Profile and History. Syntekabio is an AI and NGS-based drug development company, utilizing a genomic database and AI to predict and identify new molecular entities to develop …See details»
Syntekabio
Syntekabio is an AI new drug development company based on genomic big data. Syntekabio USA Inc. 425 Fifth Ave. Suite 505 New York, NY 10016; TEL : +1 (212) 371-2544; FAX : +1 (917) …See details»
Syntekabio, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Syntekabio, Inc. of Daejeon, Daejeon. Get the latest business insights from Dun & Bradstreet.See details»
Syntekabio - VentureRadar
"Syntekabio, a genomic big data and AI-driven drug development company, headquartered in Daejeon, South Korea. Area of focus includes AI-guided small molecule drug candidate …See details»
Syntekabio Inc. - LinkedIn
Syntekabio Inc. Biotechnology Research New York, NY 870 followers AI Platform for Drug Discovery & Precision Medicine (226330:KOSDAQ)See details»
Syntekabio Company Profile - Craft
Syntekabio â‚©243.99 m in annual revenue in FY 2022. See insights on Syntekabio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Syntekabio Company Profile 2024: Stock Performance & Earnings
Syntekabio General Information Description. SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on …See details»
Syntekabio
Syntekabio begins its leap to become a leading player in the fourth biohealth industry. Genome big data company Syntekabio has been striving to establish a precision medicine and AI new …See details»
Syntekabio - Overview, News & Similar companies | ZoomInfo.com
Aug 12, 2022 Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting Syntekabio (KOSDAQ: 226330), an AI and NGS based drug …See details»
Syntekabio - Contacts, Employees, Board Members, Advisors
Syntekabio is a public company, listed on the KOSDAQ. It is an AI drug discovery and development company based on genomic big data.See details»
Syntekabio - Products, Competitors, Financials, Employees, …
Syntekabio collaborates with academic institutions, industrial companies, and government research labs to create transformative medicines. Syntekabio was formerly known as Yoobiori. …See details»
Syntekabio to hold extraordinary general meeting on business …
2 days ago Syntekabio, a Korean AI-driven drug development company, announced plans to hold an extraordinary general meeting (EGM) on Jan. 23, 2025, to amend its articles of …See details»
Syntekabio
Syntekabio is an AI new drug development company based on genomic big data. History. Present - 2019; 2018 - 2015; 2014 - 2009; 2023; 2022; 2021; 2020; 2019; 2023. 9. Completion of the …See details»
Syntekabio to Showcase Innovative AI Drug Discovery …
Apr 11, 2024 About Syntekabio. Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first …See details»
Syntekabio to Showcase Advanced AI Drug Discovery …
May 23, 2024 Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in …See details»
Syntekabio
Syntekabio USA. Our goal is to impeccably execute customer-centric roles, endeavoring to forge robust customer relationships grounded in mutual trust and respect. Through consistently …See details»